+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 1Month +
All Genders
ID06998524

Evaluation of Emicizumab Prophylaxis Compared to Standard On-Demand Therapy in Type 3 Von Willebrand Disease Patients

Led by Hoffmann-La Roche · Updated on 2026-10-09

75

Participants Needed

29

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, and how the body processes emicizumab when used as preventive treatment in people aged 1 month and older diagnosed with Type 3 von Willebrand disease VWD. This Phase III open-label study compares emicizumab prophylaxis with standard on-demand therapies in participants previously receiving on-demand treatment, and also assesses emicizumab in participants who were on prophylactic therapy using data from a prior non-interventional study. Participants in the study are assigned to one of three groups those switching from on-demand treatment to emicizumab injections given under the skin weekly or every two weeks those continuing their current on-demand therapy for 24 weeks and those previously on prophylactic treatment who will receive emicizumab prophylaxis. After 24 weeks, participants benefiting from emicizumab or completing on-demand treatment may continue emicizumab during an extension period. Other treatments like von Willebrand factor and Factor VIII concentrates or bypassing agents may be used according to local guidelines. Throughout the study, participants will attend visits for assessments including bleeding rates, side effects, blood tests, heart and respiratory monitoring, and questionnaires on pain and fatigue. These evaluations occur regularly from the start of treatment through the study period, which may extend up to nearly 4 years. Researchers will closely monitor safety, drug levels, immune responses, and the impact of treatment on bleeding to understand the treatments effects over time.

CONDITIONS

Brief Title

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Research Team

R

Reference Study ID Number: WP45338 https://forpatients.roche.com/

F

Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here